Savara Inc Income Tax Expense
Savara Inc (SVRA) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-13
- Savara Inc income tax expense (benefit) for the quarter ending 2018-12-31 was $2.50M.
- Savara Inc income tax expense (benefit) for the quarter ending 2018-09-30 was -$110.00K.
- Savara Inc income tax expense (benefit) for the quarter ending 2018-06-30 was -$277.00K.
- Savara Inc income tax expense (benefit) for the quarter ending 2018-03-31 was -$4.55M.
- Savara Inc income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Savara Inc income tax expense (benefit) for fiscal 2024 was $9.00K.
- Savara Inc income tax expense (benefit) for fiscal 2018 was -$7.06M.
- Savara Inc income tax expense (benefit) for fiscal 2017 was -$3.63M.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-13 | |||||||
| 2024-12-31 | $9.00K 10-K · filed 2026-03-13 | |||||||
| 2018-12-31 | $2.50M 10-K · filed 2020-03-12 | $1.80M 10-K · filed 2019-03-13 | $2.39M derived: sum of 2 quarters · filed 2020-03-12 | $2.11M derived: sum of 3 quarters · filed 2020-03-12 | -$7.06M 10-K · filed 2020-03-12 | -$8.51M 10-K · filed 2019-03-13 | ||
| 2018-09-30 | -$110.00K 10-Q · filed 2018-11-07 | -$387.00K derived: sum of 2 quarters · filed 2018-11-07 | -$4.55M 10-Q · filed 2019-11-07 | -$5.87M 10-Q · filed 2018-11-07 | -$7.75M derived: sum of 4 quarters · filed 2019-05-09 | |||
| 2018-06-30 | -$277.00K 10-Q · filed 2018-08-09 | -$4.55M 10-Q · filed 2019-08-08 | -$5.76M 10-Q · filed 2018-08-09 | -$7.64M derived: sum of 3 quarters · filed 2019-05-09 | -$7.76M derived: sum of 4 quarters · filed 2019-05-09 | |||
| 2018-03-31 | -$4.55M 10-Q · filed 2019-05-09 | -$5.48M 10-Q · filed 2018-05-09 | -$7.37M derived: sum of 2 quarters · filed 2019-05-09 | -$7.48M derived: sum of 3 quarters · filed 2019-05-09 | -$7.95M derived: sum of 4 quarters · filed 2019-05-09 | |||
| 2017-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$2.93M derived: sum of 2 quarters · filed 2019-03-13 | -$3.40M derived: sum of 3 quarters · filed 2019-03-13 | -$3.63M 10-K · filed 2019-03-13 | ||||
| 2017-09-30 | -$117.00K 10-Q · filed 2018-11-07 | -$587.00K derived: sum of 2 quarters · filed 2018-11-07 | -$824.00K 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | -$470.00K 10-Q · filed 2018-08-09 | -$707.00K 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$237.00K 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | -$357.00K 10-K · filed 2018-03-14 | -$2.41M 10-K · filed 2017-03-06 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-06 | |||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-06 | |||||||
| 2013-12-31 | $0.00 10-K · filed 2015-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |